In the metastatic setting, increased MET copy numbers correlate with trastuzumab therapy failure in ERBB2-positive breast cancer [41] and clinical trials with anti-MET therapy in advanced breast cancer are ongoing [42]. Here, ERBB2 is linked to breast carcinoma.